LYL273 for Patients With Relapsed or Refractory mCRC
ConditionColorectal Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorLyell Immunopharma, Inc.
About this trial
This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.
Eligibility criteria
Qualifiers
Adults > 18 years old
Clinical and histopathological diagnosis of relapsed or refractory metastatic colorectal cancer
Eastern Cooperative Oncology Group performance status of 0 or 1
Limited liver disease (less than 7 lesions with largest lesion less than 3 cm)
Disqualifiers
Participants with tumor lesion(s) in a location that may cause perforation of an organ or structure (such as the digestive tract, urinary bladder, or blood vessel) with LYL273 therapy
Active central nervous system (CNS) involvement by malignancy on magnetic resonance imaging (MRI) or contrast-enhanced computed tomography (CT)
History of or active viral infection including human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, cerebral edema, posterior reversible encephalopathy syndrome, or any autoimmune disease with CNS involvement in the 2-year period leading up to the study enrollment
Trial design
Treatments tested in this trial
- LYL273
Treatment groups
155 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov